GlaxoSmithKline has begun a phase III clinical study that will compare comparing its drug Tykerb with Herceptin in the treatment of early breast cancer. The trial will measure which cancer cells disappear in the breast following treatment with Tykerb and/or Herceptin before surgery in women with early-stage breast cancer whose tumours overexpress the HER2 protein.
Glaxo tests Tykerb versus Herceptin for early Breast Cancer Treatment
Herceptin has been the star of breast cancer treatment in the past 2 years. Tykerb (lapatinib) claims to be a superior treatment. Women who have recently been diagnosed with breast cancer should ask their oncologists about both drugs since early treatment can be important in beating the disease.
Wayne Parsons
A resident of Honolulu, Hawaii, Wayne Parsons is an Injury Attorney that has dedicated his life to improving the delivery of justice to the people of his community and throughout the United States.
All articles
Tags:
FDA & Prescription Drugs
More in FDA & Prescription Drugs
See all
More from Wayne Parsons
See all
